Building the case for novel clinical trials in pulmonary arterial hypertension.
作者信息
Ryan John J, Rich Jonathan D, Maron Bradley A
机构信息
From the Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City (J.J.R.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (J.D.R.); Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.A.M.); and Department of Cardiology, Boston VA Heathcare System, Boston, MA (B.A.M.).
出版信息
Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):114-23. doi: 10.1161/CIRCOUTCOMES.114.001319.
Abstract
摘要
相似文献
1
Building the case for novel clinical trials in pulmonary arterial hypertension.
Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):114-23. doi: 10.1161/CIRCOUTCOMES.114.001319.
2
A paradigm shift in pulmonary arterial hypertension management.
Eur Respir Rev. 2013 Dec;22(130):423-6. doi: 10.1183/09059180.00006913.
3
Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal.
Eur Respir Rev. 2012 Sep 1;21(125):259-62. doi: 10.1183/09059180.00003612.
4
Pulmonary hypertension-"state of the art" management in 2012.
Indian Heart J. 2012 Jan-Feb;64(1):60-73. doi: 10.1016/S0019-4832(12)60013-3. Epub 2012 Mar 26.
5
Diagnosis and treatment of pulmonary hypertension.
Heart. 2015 Feb;101(4):311-9. doi: 10.1136/heartjnl-2011-301386. Epub 2014 May 22.
6
Future perspectives in pulmonary arterial hypertension.
Eur Respir Rev. 2016 Dec;25(142):381-389. doi: 10.1183/16000617.0084-2016.
7
Use of β-Blockers in Pulmonary Hypertension.
Circ Heart Fail. 2017 Apr;10(4). doi: 10.1161/CIRCHEARTFAILURE.116.003703.
8
Heartbeat: Biomarkers and pulmonary artery hypertension.
Heart. 2016 Mar;102(5):333-4. doi: 10.1136/heartjnl-2015-309220.
9
Macitentan for the treatment of pulmonary arterial hypertension.
Drugs Today (Barc). 2014 Jun;50(6):401-6. doi: 10.1358/dot.2014.50.6.2146837.
10
Diagnostic and Treatment Advances for Chronic Thromboembolic Pulmonary Hypertension.
Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):194. doi: 10.14797/mdcj-12-4-194.
引用本文的文献
1
The sine transform is the of the pulmonary and systemic pressure relationship.
Front Cardiovasc Med. 2023 May 26;10:1120330. doi: 10.3389/fcvm.2023.1120330. eCollection 2023.
2
Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Pediatr Pulmonol. 2022 Mar;57(3):724-733. doi: 10.1002/ppul.25796. Epub 2022 Jan 3.
3
Clinical trial design in phase 2 and 3 trials for pulmonary hypertension.
Pulm Circ. 2020 Jul 20;10(4):2045894020941491. doi: 10.1177/2045894020941491. eCollection 2020 Oct-Dec.
4
Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy.
Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202008. doi: 10.21542/gcsp.2020.8.
5
Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
Am J Respir Crit Care Med. 2021 Mar 15;203(6):726-736. doi: 10.1164/rccm.202002-0357OC.
6
Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?
Pulm Circ. 2019 Apr-Jun;9(2):2045894019845615. doi: 10.1177/2045894019844994.
7
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.
Pulm Circ. 2017 Apr-Jun;7(2):312-325. doi: 10.1177/2045893217710639. Epub 2017 May 30.
8
Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.
9
The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series).
Pulm Circ. 2016 Sep;6(3):274-84. doi: 10.1086/687765.
10
Update in Pulmonary Vascular Disease 2015.
Am J Respir Crit Care Med. 2016 Jun 15;193(12):1337-44. doi: 10.1164/rccm.201601-0143UP.
本文引用的文献
1
The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.
Pulm Circ. 2014 Sep;4(3):441-51. doi: 10.1086/677357.
2
The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials.
Eur Heart J. 2014 Aug 7;35(30):2001-9. doi: 10.1093/eurheartj/ehu205. Epub 2014 Jun 5.
3
N-of-1 (single-patient) trials for statin-related myalgia.
Ann Intern Med. 2014 Mar 4;160(5):301-10. doi: 10.7326/M13-1921.
4
An official American Thoracic Society Statement: pulmonary hypertension phenotypes.
Am J Respir Crit Care Med. 2014 Feb 1;189(3):345-55. doi: 10.1164/rccm.201311-1954ST.
5
New trial designs and potential therapies for pulmonary artery hypertension.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D82-91. doi: 10.1016/j.jacc.2013.10.026.
6
Updated treatment algorithm of pulmonary arterial hypertension.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-72. doi: 10.1016/j.jacc.2013.10.031.
7
Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029.
8
Genetics and genomics of pulmonary arterial hypertension.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D13-21. doi: 10.1016/j.jacc.2013.10.035.
9
Pulmonary hypertension: pathophysiology and signaling pathways.
Handb Exp Pharmacol. 2013;218:31-58. doi: 10.1007/978-3-642-38664-0_2.
10
A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.
Pulm Circ. 2013 Apr;3(2):381-8. doi: 10.4103/2045-8932.114768.
Zotero 插件